LA JOLLA, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Immunosyn Corporation (OTC Bulletin Board: IMYN) announced that its stock will begin over-the- counter trading on Friday, October 26, 2007. The company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, distribute and sell the biopharmaceutical SF-1019.
"Having gone public in January this year, we are pleased to start trading as we begin to develop the distribution lines for a product as important as SF-1019," noted Stephen Ferrone, Immunosyn's CEO.
About Immunosyn Corporation
La Jolla, CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including auto-immune disorders such as Multiple Sclerosis (MS), neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS) and complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and Diabetic Ulcers (DU).
The above news release contains forward-looking statements. These
statements are based on assumptions that management believes are reasonable
based on currently available information, and include statements regarding
the intent, belief or current expectations of the Company and its
management. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance, and
are sub
'/>"/>
| SOURCE Immunosyn Corporation Copyright©2007 PR Newswire. All rights reserved |